The US Department of Health and Human Services’ Office of Inspector General recommends that the Food and Drug Administration improve how it uses adverse event reports for medical devices to identify and address safety concerns. The OIG’s recommendations are based on its findings of a review of adverse event reporting from 2003 to 2007, which was published in October 20091
...
Scrip Regulatory Affairs
US OIG report criticises FDA?s use of adverse event reports
05 November 2009
Jeanette Marchant
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- Will PDUFA V be a 'damned if it does, damned if it doesn't' scenario for US FDA?
- FDA report questions whether US rules can ensure quality of marketed medical devices
- PDUFA V: predictability a key theme but US FDA urged to focus on safety too
- Industry baulks at Indian ministry's call to ?pay clinical trial compensation or go?
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
